William Blair Initiates Coverage On Edgewise Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform rating.
Stocks · News reference
Edgewise Therapeutics Doses First Participant In EQUINOX-HFpEF Study Of EDG-15400 To Treat Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiometabolic diseases, today announced the dosing of the first patient in EQUINOX-HFpEF, a Phase 2 clinical
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Edgewise Therapeutics Says Preclinical Data Show Hypertrophic Cardiomyopathy Candidate EDG-7500 Improves Cardiac Relaxation While Preserving Pumping Function
HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $57
HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $45 to $57.